Advertisement: Innova Systems
Advertisement: Cambridge Enterprise mid banner
Advertisement: EBCam mid banner
Advertisement: RSM
ARM Innovation Hub
Advertisement: Cambridge Network
RealVNC mid banner careers
Advertisement: China mid banner
Barr Ellison Solicitors – commercial property
RealVNC mid-banner general
Advertisement: Cambridge Corporate Finance Club
Mid banner advertisement: BDO
Advertisement EY mid banner
Advertisement: Mogrify
23 January, 2020 - 21:26 By Kate Sweeney

PhoreMost and Otsuka in multi-project collaboration

PhoreMost, a Cambridge biopharma company dedicated to drugging ‘undruggable’ disease targets, has entered into a multi-project collaboration with Otsuka Pharmaceutical Co.

Otsuka is a world-leading pharmaceutical company dedicated to the research and development of highly-innovative drugs and diagnostics. Financial details of the agreement are not disclosed.

PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER®, towards disease relevant pathways nominated by Otsuka. 

Novel targets identified will be further validated and characterised by Otsuka as part of its internal development pipeline, with an initial focus on gene therapy applications of identified targets.

PhoreMost’s SITESEEKER platform exploits protein shape diversity to find functionally active peptides, significantly enhancing the power of phenotypic screening and translation into therapeutic modalities. 

Based on proprietary protein interference, or ‘PROTEINi®’, technology PhoreMost uses SITESEEKER to probe the entire proteome in a live cell environment for novel druggable targets linked to any chosen disease. 

This enables the systematic discovery of functionally active peptides which are directly linked to useful therapeutic applications.

Dr Chris Torrance, CEO of PhoreMost, said: “This collaboration with Otsuka is further recognition of the power of the SITESEEKER approach to drive the identification of novel, druggable targets. 

“We are particularly excited to be exploring not only small molecule therapeutics but also gene therapy applications of our platform.”

Newsletter Subscription

Stay informed of the latest news and features